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Abstract
Developmental and physiological changes in children contribute to variation in drug disposition 
with age. Additionally, critically ill children suffer from various life-threatening conditions that 
can lead to pathophysiological alterations that further affect pharmacokinetics (PK). Some factors 
that can alter PK in this patient population include variability in tissue distribution caused by 
protein binding changes and fluid shifts, altered drug elimination due to organ dysfunction, and 
use of medical interventions that can affect drug disposition (e.g., extracorporeal membrane 
oxygenation and continuous renal replacement therapy). Performing clinical studies in critically ill 
children is challenging because there is large inter-subject variability in the severity and time 
course of organ dysfunction; some critical illnesses are rare, which can affect subject enrollment; 
and critically ill children usually have multiple organ failure, necessitating careful selection of a 
study design. As a result, drug dosing in critically ill children is often based on extrapolations from 
adults or non-critically ill children. Dedicated clinical studies in critically ill children are urgently 
needed to identify optimal dosing of drugs in this population. This review will summarize the 
effect of critical illness on pediatric PK, the challenges associated with performing studies in this 
vulnerable subpopulation, and the clinical PK studies performed to date for commonly used drugs.
Keywords
clinical pharmacology; critically ill; pediatrics; pharmacokinetic alterations; organ dysfunction
*Corresponding author: Daniel Gonzalez, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, CB 
#7569, Chapel Hill, NC 27599-7569, USA. Tel: +1-919-966-9984; Fax: 919-962-0644; daniel.gonzalez@unc.edu.
aCurrent address: Bristol-Myers Squibb, Princeton, NJ, USA
CONFLICT OF INTEREST
D.G. receives support for research from the National Institute for Child Health and Human Development (K23HD083465), the 
nonprofit organization Thrasher Research Fund (www.thrasherresearch.org), and from industry (Cempra, Inc. and Jacobus 
Pharmaceutical Company, Inc.) for drug development in adults and children. C.P.H. receives salary support for research from the 
National Center for Advancing Translational Sciences of the National Institutes of Health (UL1TR001117). The remaining authors 
have no funding to disclose. The content is solely the responsibility of the authors and does not necessarily represent the official views 
of the National Institutes of Health, which had no role in study design; the collection, analysis, and interpretation of data; the writing 
of the report; or the decision to submit the manuscript for publication.
HHS Public Access
Author manuscript
Pharm Res. Author manuscript; available in PMC 2018 January 01.
Published in final edited form as:
Pharm Res. 2017 January ; 34(1): 7–24. doi:10.1007/s11095-016-2033-y.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
INTRODUCTION
Critically ill patients suffer from life-threatening medical conditions that can be associated 
with multiple organ dysfunction and a plethora of pathophysiological alterations within the 
body. Pharmacokinetics (PK) can be altered in this patient population due to variable tissue 
distribution resulting from fluid shifts, and pH and protein binding changes; drug 
elimination may also be affected in these children due to renal and hepatic dysfunction. 
Moreover, life-saving medical interventions (e.g., extracorporeal membrane oxygenation 
[ECMO]) that are used in these children can contribute to variable drug disposition. In 
addition to alterations in PK mediated by pathophysiological factors, critically ill children 
are also undergoing expected physiological and developmental changes with age.
In the absence of critical illness, normal developmental and physiological changes include 
shifts in body composition and maturation in drug elimination pathways [1–3]. Briefly, body 
size composition changes significantly from neonates to adulthood. For example, as a 
percentage of total body weight, total body water is higher and body fat is lower after birth 
relative to adults [2,4]. For hydrophilic drugs this increased percentage of total body water 
can result in a greater volume of distribution (VD) (per kilogram of body weight) in 
newborns, whereas the opposite would be true for highly lipophilic drugs [4]. Maturational 
changes in drug elimination processes occur mainly due to the ontogeny differences in 
cytochrome P450 (CYP) enzymes and/or drug transporters. For example, based on in vivo 
data, it was estimated that CYP3A4 activity does not reach adult values until about 1.3 years 
of age [5–7]. Renal function also undergoes maturational changes; for example, the 
glomerular filtration rate reaches 90% of the adult value at 1 year postnatal age [8]. An 
understanding of how these developmental factors, along with pathophysiological alterations 
due to critical illness, influence PK changes and exposure-response relationships is 
important for defining optimal dosing of drugs used in this vulnerable patient population.
In this review, an overview of the factors that can mediate PK changes in critically ill 
children are discussed, and specific challenges associated with performing clinical research 
in this patient population are noted. Last, we performed an exhaustive literature search using 
the U.S. National Library of Medicine’s PubMed (http://www.ncbi.nlm.nih.gov/pubmed) 
and summarized the relevant clinical pharmacology studies performed to date in critically ill 
children.
EFFECT OF CRITICAL ILLNESS ON PHARMACOKINETICS
Critical illness alters the disposition of drugs in children through a variety of 
pathophysiologic mechanisms (Figure 1). First, tissue distribution may be altered due to 
changes in protein concentrations, blood pH, fluid shifts, and abnormal capillary 
permeability [9,10]. Drug elimination may be affected by disease related changes in organ 
function (e.g., heart, kidneys, and liver). Last, use of life saving medical interventions 
applied in critically ill children, such as ECMO or continuous renal replacement therapy 
(CRRT) may profoundly alter the physiologic balance, further affecting drug disposition.
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Alterations in Protein Binding
Changes in protein binding can alter tissue distribution by affecting the fraction of drug that 
is unbound and able to diffuse into tissues [11]. With critical illness both the synthesis and 
binding affinity of albumin and α-1 acid glycoprotein (AAG), the predominant drug binding 
proteins, may change as a result of liver or kidney dysfunction [12–14]. The following are 
examples of medications with a high degree of protein binding (% protein bound) used in 
critically ill children: ticarcillin (65%), daptomycin (93–98%), teicoplanin (98%), 
vancomycin (10–50%), oseltamivir (42%), lorazepam (83%), phenytoin (90%), midazolam 
(95–98%), and propofol (97–98%) [15–25]. These drugs may undergo protein binding 
changes in the presence of critical illness. For example, children with acute traumatic brain 
injury were shown to have significantly altered phenytoin protein binding [26,27].
pH Changes
Acute and chronic respiratory and metabolic acidosis or alkalosis are common pH 
derangements seen in critically ill children [28,29]. Changes in pH can occur as a result of 
respiratory dysfunction with carbon dioxide retention, altered renal function with electrolyte 
imbalance, hypoperfusion with secondary tissue acidosis, or primary metabolic diseases 
[30]. The pH of individual body compartments, such as the stomach or urine, can also be 
altered in critically ill children secondary to pharmacological treatment or fluid replacement. 
The acid dissociation constant (pKa) of a drug dictates the ionization state and distribution at 
different pH levels. Changes in pH in a specific body compartment may affect drug 
disposition. For example, methadone, a basic compound (pKa=9.2) administered to critically 
ill children for opioid abstinence syndrome is mainly unionized in acidic urine and its 
elimination can be enhanced by acid diuresis that may be observed with critical illness [31].
Fluid Shifts
Critical illness frequently results in marked fluid shifts as a result of altered capillary 
permeability or perturbations of the oncotic and hydrostatic forces (Starling forces) [32–34]. 
Disease states such as inflammation, infection, sepsis, liver cirrhosis, renal failure, and 
congestive heart failure can lead to increased capillary permeability due to direct injury or in 
response to the inflammatory cascade. Increased intravascular hydrostatic pressure resulting 
from fluid overload, and decreased tissue oncotic pressure secondary to hypoproteinemia, 
are also commonly seen in critically ill children. In isolation or in combination, these 
mechanisms result in a net shift of fluid from the intravascular to the interstitial and 
extravascular spaces [10,28,35]. Manifestations of these fluid shifts include ascites, pleural 
effusion, and edema, which can profoundly alter drug distribution. The VD of hydrophilic 
antibiotics (e.g., aminoglycosides, beta-lactams) may be increased in critically ill patients 
due to these fluid shifts. The increased VD can reduce the maximum concentration of 
antibiotics and thereby affect the pharmacodynamic (PD) outcome. For example, the VD of 
amikacin and gentamicin have been reported to be increased in critically ill children 
receiving fluid replacement therapy due to increased capillary hydrostatic pressure and fluid 
shits [36,37].
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Renal Dysfunction
Acute kidney injury (AKI) is a prevalent comorbidity in critically ill children characterized 
by an abrupt decline in renal function. As many as 5.7% of children admitted to the pediatric 
intensive care unit (PICU) exhibit at least some degree of AKI at the time of admission, and 
10% of children develop AKI during their PICU stay [38]. In addition to new onset AKI, 
children with chronic kidney disease (CKD) or end stage renal disease (ESRD) are 
frequently admitted to the PICU in critical condition as a result of renal disease exacerbation 
or comorbidities [39–42]. Alterations in renal function affect many factors that influence the 
PK of drugs, including impaired renal clearance, enzyme activity, pH changes, and 
alterations in total body water. For example, AKI is characterized by fluid retention and 
metabolic acidosis [43–46]. These changes may affect the fraction of drug ionized and alter 
the tissue distribution and VD of drugs. Together, these mechanisms lead to an altered VD 
and renal clearance of drugs. For some disease states such as sepsis, traumatic brain injury, 
and burns, augmented renal clearance (ARC) can also occur. While the exact 
pathophysiologic mechanisms resulting in ARC remain unknown, increased renal blood 
flow due to underlying illness or as a result of pharmacologic interventions are likely 
responsible. ARC has been identified in as many as 65% of adults admitted to a tertiary level 
ICU, and has been shown to lead to increased renal clearance of some antibiotics in critically 
ill children [47,48]. The PK of drugs administered to critically ill children (e.g., antibiotics, 
opioids, anticonvulsants) have been reported to be altered due to renal disease and thus 
appropriate dose adjustments are warranted based on a patient’s clinical presentation and the 
extent to which renal function is altered [49–51].
Hepatic Dysfunction
Several hepatic diseases may occur in critically ill children, including acute liver failure, 
viral or metabolic hepatitis, and cirrhosis [52]. While milder forms of hepatic dysfunction 
are generally well tolerated, acute liver failure is rare but a potentially fatal medical 
emergency. Acute liver failure leads to profound physiologic alterations that affect drug 
disposition, including severe capillary leak, coagulopathy, renal dysfunction, and 
hypoglycemia. Milder forms of hepatic dysfunction can also alter drug PK due to changes in 
hepatic blood flow, hepatic enzyme activity, hepatic drug transport, protein binding, and 
alterations in total body water [3,43,53,54]. Changes in the activity of hepatic enzymes can 
alter the PK of drugs primarily metabolized in the liver [54,55]. In addition to altered 
metabolism, liver dysfunction may also result in decreased synthesis of albumin and AAG, 
leading to reduced plasma concentrations and altered unbound fractions of drugs [56,57]. 
Increased unbound fractions of drugs such as alfentanil, phenytoin, and morphine have been 
reported in adults with hepatic dysfunction [58,59]. Finally, impaired protein synthesis and 
hepatic blood flow resulting from liver disease can cause fluid shifts and ascites, which can 
affect the VD of hydrophilic drugs such as aminoglycoside antibiotics [3,60,61]. All of the 
above changes may be particularly relevant for drugs undergoing extensive hepatic first pass 
metabolism (e.g., antibiotics, opioids, anticonvulsants) [49–51]. Finally, hepatic function 
may also be affected by iatrogenic alterations in hepatic blood flow, including reduced flows 
in states of increased intrathoracic pressure secondary to mechanical ventilation, or 
decreased hepatic perfusion secondary to vasoconstriction by vasopressors (vasopressin, 
phenylephrine, norepinephrine) [62–66].
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Altered Hepatic Metabolism in Other Disease Conditions
Alterations in hepatic metabolism may occur in critically ill children even in the absence of 
hepatic failure. Inflammatory mediators released during sepsis have been shown to reduce 
cytochrome P450 mediated metabolism of antipyrine in critically ill children [67]. Similar 
inflammation may also occur in the setting of traumatic brain injury, altering the hepatic 
metabolism of phenytoin [26,27]. In addition to alerting drug disposition, inflammatory 
mediators such as nitric oxide may also directly reduce drug efficacy [68]. Lastly, the hepatic 
metabolism of high extraction ratio drugs such as propofol may be particularly vulnerable to 
changes in hepatic blood flow resulting from cardiovascular and other diseases [69].
Cardiovascular Diseases
Both congenital heart defects and acquired heart disease can result in cardiac dysfunction 
and congestive heart failure (CHF) requiring PICU admission [70,71]. CHF affects drug 
distribution by altering cardiac output and impairing blood flow to drug clearing organs, 
such as the liver and kidneys. Both hepatic and renal perfusion pressure may be reduced due 
to increased central venous pressure resulting from cardiac dysfunction, which further 
affects organ function. This may result in impaired drug clearance (CL). CHF is also 
associated with fluid overload, edema, and increased AAG concentrations, factors that can 
contribute to altered drug distribution [72–74]. Lastly, abdominal venous congestion may 
impair enteral absorption of drugs, which has been demonstrated for the loop diuretic 
furosemide [75].
Extracorporeal Membrane Oxygenation (ECMO)
ECMO is a life support technique used in critically ill patients with serious respiratory and 
cardiac conditions [76]. ECMO is an adaptation of cardiopulmonary bypass where blood is 
drained from the patient’s venous system, pumped into an oxygenator via tubing in the 
ECMO circuit, and returned back to the arterial or venous system [77–79]. Critically ill 
children may require ECMO under various conditions, including pneumonia, sepsis, 
congenital heart disease, and pulmonary abnormalities, and may thus be exposed to 
numerous drugs [80]. Several studies have shown that ECMO use in critically ill children 
alters the disposition of drug classes discussed in this review (antibiotics, analgesics, 
anticonvulsants, and sedatives) [81–91]. For example, VD may be increased in critically ill 
children because of the added volume of the ECMO circuit, as demonstrated for several 
antibiotics (e.g., vancomycin and gentamicin) [81–84,91]. Additionally, in vitro studies have 
shown that lipophilic drugs (e.g., midazolam and fentanyl) are adsorbed to the tubing in the 
ECMO circuit, which may lead to increased VD in critically ill children [85–87]. ECMO 
may also lead to increased variability of VD and CL. Lastly, renal and hepatic dysfunction 
are common complications of ECMO support in children, and may impact the CL of drugs 
used in this patient population (e.g., vancomycin and gentamicin) [64,77–80]. Under the 
most severe circumstances, patients may be concomitantly supported with ECMO and 
CRRT, further altering drug disposition [92].
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Continuous Renal Replacement Therapy (CRRT)
Renal replacement therapy is indicated for patients with severe AKI experiencing volume 
overload, electrolyte imbalances, or accumulation of toxins or toxic metabolites. CRRT is a 
form of renal replacement therapy intended for continuous, around-the-clock use. Because 
of its continuous use, CRRT is typically better tolerated by critically ill children than other 
forms of renal replacement therapy [93,94]. Multiple factors can affect drug CL in critically 
ill children receiving CRRT, including drug and patient characteristics, and the type of 
CRRT modality employed [95]. The small pore size of the dialysis or hemofiltration 
membranes limits dialysis or filtration to the unbound fraction of drugs. As a result, drugs 
with low protein binding are more readily removed by CRRT. Drug clearance by CRRT may 
also be increased in the setting of hypoproteinemia associated with critical illness. Drugs 
with a smaller VD, which are predominantly concentrated in the plasma, will also be cleared 
more readily by CRRT than drugs with extensive tissue distribution [96]. In addition to drug 
properties, changes in blood or dialysate flow rate can affect transmembrane pressure and 
drug CL [97,98]. Additionally, some dialysis membranes can adsorb drugs in hemofiltration 
[97]. Previous studies have shown that the PK of meropenem and ticarcillin were altered in 
critically ill children supported with CRRT [99,100].
CHALLENGES ASSOCIATED WITH PERFORMING STUDIES IN CRITICALLY 
ILL CHILDREN
In spite of the extensive use of drugs in critically ill children, PK studies to inform 
appropriate dosing are limited. This is largely due to the challenges associated with 
conducting clinical studies in the pediatric population and specifically in critically ill 
children (Figure 2) [101,102]. In general, challenges associated with performing clinical 
trials in children include low consent rates, limited blood volume, and small number of 
subjects with a given disease. These challenges are typically magnified in critically ill 
children.
Performing clinical trials in critically ill children has additional challenges. First, critically 
ill children usually have multiple organ failure, necessitating careful selection of a study 
design. Unfortunately, there is often limited safety, efficacy and target exposure information 
of drugs used in critically ill children, which further complicates the design of clinical 
studies. Also, the effect of critical illness on PK can vary from adults, making extrapolation 
of available information difficult. Second, many critical illnesses are relatively rare, which 
further complicates subject enrollment. Third, the time varying nature of many critical 
illnesses requires that subjects be followed for a longer period of time and appropriate 
measure of disease function be collected. Last, critically ill children are administered a wide 
array of concomitant medications and are undergoing medical interventions that can alter the 
PK of drugs studied and confound the drug effects of interest.
PHARMACOKINETIC STUDIES IN CRITICALLY ILL CHILDREN
Clinical pharmacology studies in critically ill children have been performed for drugs widely 
used in this patient population. In many cases there were significant PK alterations in 
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critically ill children relative to non-critically ill children or adults. The PK alterations of 
anti-infectives and non-anti-infectives are summarized in Tables I and II, respectively. 
Alterations in weight-normalized CL and VD compared to those in non-critically ill children 
obtained from the literature (or in adults when PK parameters were not available for non-
critically ill children) are presented. In some cases the PK is highly variable in critically ill 
children and therefore no trends could be detected. The following section summarizes the 
PK alterations of anti-infectives and non-anti-infectives drugs studied in critically ill 
children.
Aminoglycosides
Aminoglycoside antibiotics are prescribed to infants and children to treat serious Gram-
negative infections including sepsis, meningitis, complicated intra-abdominal or urinary tract 
infections, and pulmonary exacerbations of cystic fibrosis [103]. Aminoglycosides are 
highly polar cations that are primarily excreted unchanged in the urine by glomerular 
filtration. They have infrequently been associated with nephrotoxicity and ototoxicity, and 
most PK studies in critically ill children have focused on optimizing dosing to minimize 
toxicity risk while maintaining efficacy.
Amikacin—Amikacin is particularly effective against gentamicin-resistant organisms 
(Enterobacteriaceae, Pseudomonas aeruginosa, and Serratia marcescens) and has been 
studied in critically ill children ranging from 1 week to 17 years of age. The mean amikacin 
CL ranged from 0.063 to 0.085 L/hr/kg and the mean central VD ranged from 0.18 to 0.24 
L/kg [104,105]. Critically ill children had larger VD estimates and prolonged elimination 
half-lives compared to non-critically ill adults, possibly due to localized or generalized 
edema [104]. Among pediatric burn patients, the CL of amikacin was increased compared to 
healthy adult volunteers; however, amikacin concentrations were comparable to other 
critically ill children [105].
Gentamicin—Gentamicin is a widely used aminoglycoside and it has been studied 
extensively in critically ill neonates [106–110] and children up to 15 years of age [111,112]. 
The mean gentamicin CL ranged from 0.028 to 0.07 L/hr/kg, the mean half-life ranged from 
3.85 to 9.23 hours, and the mean or median central VD ranged from 0.39 to 0.98 L/kg [106–
108,112]. In comparison, non-critically ill children had a mean CL of 0.042 L/hr/kg, mean 
half-life ranging from 2–8 hours, and a mean VD ranging from 0.3–0.43 L/kg [113,114]. 
Similar to amikacin, critically ill children have an extended half-life due at least in part to 
the larger VD. Volume expansion during critical illness could be a result of capillary leak 
associated with sepsis and septic shock causing peripheral edema, excess fluid administered 
to prevent hypotension, and fluid retention during sepsis and renal failure. However, one 
study reported that gestational age, but not fluid intake, correlated with CL or VD in 
critically ill neonates with sepsis, while fluid retention was negatively correlated with Cmax 
[106].
Furthermore, a study performed in newborn infants ≥ 37 weeks gestational age receiving 
high-frequency mechanical ventilation and conventional mechanical ventilation found that 
infants receiving high-frequency mechanical ventilation had a slower mean (±standard 
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deviation) (± SD) elimination rate constant [0.081 (± 0.02) versus 0.10 hr−1 (± 0.02)], a 
prolonged mean half-life [9.23 (±2.91) versus 7.07 hours (± 1.14)], more rapid clearances 
[(0.07 (± 7.04) versus 0.05 (± 0.01) L/hr/kg], and a larger mean VD [(0.98 (± 0.46) versus 
0.49 (±0.09) L/kg)] compared to infants receiving conventional mechanical ventilation 
[107]. The authors hypothesized that patients receiving high frequency mechanical 
ventilation might have an increased half-life due to decreased cardiac output and renal blood 
flow, resulting in impaired renal elimination of gentamicin [107]. These PK changes might 
also be influenced by the higher severity of illness in infants receiving high-frequency 
mechanical ventilation, although the study did try to control for severity of illness by only 
including infants that received a full 7–10 course of therapy [107]. The serum creatinine was 
slightly higher in the high-frequency mechanical ventilation group compared to the 
conventional mechanical ventilation group but it did not reach statistical significance [107].
Netilmicin—Netilmicin is considered to have the lowest potential for nephrotoxicity and 
ototoxicity of all aminoglycosides [115]. Critically ill neonates given netilmicin along with 
fluid therapy or parenteral nutrition during the first week of life had a mean VD of 0.46–0.53 
L/kg, half-life of 6.8–12.8 hours, and CL of 0.03–0.05 L/hr/kg [116]. There was no 
statistically significant difference between the PK parameters of netilmicin among neonates 
receiving either fluid therapy or parenteral nutrition [116]. Non-critically ill newborns had a 
slightly smaller mean VD (0.41–0.52 L/kg), a shorter mean half-life (4.6–8.5 hours) and 
similar mean CL (0.04–0.06 L/hr/kg) [117–119]. The slightly higher VD in critically ill 
neonates was possibly due to an expansion of the extracellular compartment from the 
hypertonic osmotic load administered during parenteral nutrition [116]. Another study 
performed in critically ill children (1 day to 15.5 years of age) reported that the majority 
(65%) of children with elevated trough levels had acute onset of renal insufficiency [120]. 
This can be expected since netilmicin is excreted by the kidneys.
Beta-lactam antibiotics
Cefotaxime—Cefotaxime is an antibiotic used in neonates on ECMO because it is active 
against many of the pathogens involved in neonatal and ECMO-related infections. In 37 
neonates receiving cefotaxime and on ECMO with a median (range) post-natal age of 3.3 
days (0.67–199), the median (range) CL, VD, and half-life were 0.36 L/h (0.19–0.75), 1.82 L 
(0.73–3.02), and 3.5 hours (1.6–6.8), respectively [121]. Although cefotaxime CL was 
similar to non-ECMO treated neonates (0.36 L/h versus 0.2–0.55 L/h), the VD was larger 
(1.82 L versus 0.68 to 1.14 L) relative to non-ECMO treated [121–124]. The authors 
suggested that hemodilution or capillary leakage of protein-bound drug into the 
extravascular compartment might have increased the VD in ECMO treated neonates, 
especially in the early phase of ECMO.
Imipenem—Imipenem-cilastatin was the first carbapenem approved for use in children, 
including neonates, and dosing recommendations are supported by adequate and well-
controlled studies [125,126]. One study reported that the PK of imipenem in critically ill 
children (median [range] age of 0.8 years [0.02 to 12.9]) was highly variable with 
unpredictable plasma concentrations observed in several children [127]. The mean (± SD) 
steady-state half-life, CL and VD were 1.35 hours (± 0.38), 0.34 L/h/kg (± 0.14), and 0.46 
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L/kg (± 0.25), respectively [127]. These values were similar to the values reported in other 
non-critically ill children and healthy adults [125,126]. Nonetheless, some physiological 
parameters during critical illness altered imipenem PK, including blood pressure, creatinine 
clearance, and bicarbonate and lactate levels. For instance, elimination rates were reduced in 
patients with high lactate and low bicarbonate levels, possibly due to poor perfusion to the 
kidneys, and elimination rates correlated with creatinine clearance [127].
Meropenem—Meropenem is approved to treat bacterial meningitis, intra-abdominal 
infections, and complicated skin infections in pediatric patients 3 months of age and older 
[128]. Meropenem has also been studied in children with CRRT and ECMO [99,129]. Peak 
meropenem concentrations were decreased in children receiving CRRT with fluid overload 
by an average of 6.1% in patients with 10% fluid overload, 11.5% with 20% fluid overload, 
and 16% with 30% fluid overload [99]. However, fluid overload did not affect CL or the 
target attainment of 40% and 75% time above the minimum inhibitory concentration (4 
mg/mL) [99]. In addition, a single case report in an 8 month old male infant on ECMO 
suggests that meropenem CL (4.14, 4.88, and 4.52 mL/kg/min on day 1 (8 h), day 3 (72 h), 
and day 9 (216 h), respectively) was slightly higher than estimates from healthy volunteers 
(4 mL/kg/min) [129].
Piperacillin—Piperacillin/tazobactam is broad spectrum antibiotic frequently prescribed as 
empiric therapy in critically ill children. Despite its frequent use, only one study has 
evaluated the population PK in critically ill children (median [range] age of 2 years [9 
months–6 years]) [130]. The mean (± SD) estimates for piperacillin CL, volume of the 
central compartment, and elimination half-lives were 0.299 (± 0.128) L/hr/kg, 0.249 
(± 0.211) L/kg, and 1.39 (± 0.62) h, respectively [130]. The piperacillin CL and VD in these 
critically ill children were similar to those reported in non-critically ill children aged 6 
months through 12 years of age [130,131]. These non-critically ill children had a CL ranging 
from 0.282 to 0.354 L/hr/kg and a VD ranging from 0.28–0.30 L/kg [131].
Ticarcillin—Ticarcillin is a beta-lactam used in children for serious infections such as 
septicemia, peritonitis, and bone and skin infections. Limited PK studies have been 
published in critically ill children receiving ticarcillin. The PK has been studied in three 
children (ages 6, 6.5, and 16 years of age) receiving ticarcillin and two of the three children 
also received CRRT and ECMO. The mean (± SD) VD and CL for ticarcillin was 0.26 
(± 0.01) L/kg and 0.038 (± 0.003) L/kg/hr, respectively [100]. The VD and non-renal CL of 
ticarcillin was comparable to patients with cystic fibrosis and healthy adult patients [132].
Lipopeptides
Daptomycin—Daptomycin is a lipopeptide antibiotic used for the treatment of 
complicated skin infections, bacteremia, meningitis and endocarditis. There is limited 
information about the PK of daptomycin in critically ill children. A single case report has 
reported the PK of daptomycin in a 13 year old male with vancomycin-resistant 
Enterococcus faecium endocarditis receiving 8 mg/kg of daptomycin [133]. His estimated 
renal clearance was approximately 120 mL/min/1.73 m2 or higher. This critically ill 
adolescent had a faster elimination rate, shorter half-life, and an increased CL with similar 
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VD compared to healthy adults. The steady state half-life, CL, VD and area under the curve 
(AUC) from 0–24 hrs in this critically ill child were 4.58 hrs, 13.47 mL/h/kg, 0.089 L/kg and 
593.92 μg*hr/mL [133]. In comparison, the average half-life, CL, VD and AUC from 0–24 
hrs in healthy adults receiving 8 mg/kg were 9.0 hours, 7.2 mL/h/kg, 0.092 L/kg, and 1130 
μg*hr/mL, respectively. The increase in CL for this critically ill adolescent compared to 
healthy adults may be due to age related differences in renal function or ARC during critical 
illness [134].
Glycopeptides
Vancomycin—Vancomycin is a glycopeptide antibiotic used for the treatment of serious 
Gram-positive infections such as methicillin-resistant staphylococci bacteremia, skin and 
soft tissue infections, and staphylococcal endocarditis. Vancomycin PK has been well 
studied in critically ill children as well as in infants receiving ECMO and CRRT [84,135–
138]. In critically ill children the mean VD ranged from 0.44 to 0.81 L/kg, the mean (± SD) 
CL was 1.95 (± 1.1) mL/kg/min, and the mean half-life ranged from 3.1 to 5.3 hours 
[136,137]. These values are relatively similar to those reported in healthy adults: mean 
systemic CL of 1.84 mL/min/kg and a mean central compartment VD of 0.584 L/kg [139]. 
However, the VD may be altered in critically ill children. Fluid resuscitation is often 
administered to critically ill patients due to the systemic inflammatory response and this can 
be expected to increase extravascular volume. One study reported that children with a 
positive fluid balance had higher vancomycin VD compared to children with a negative fluid 
balance (0.6 L/kg versus 0.3 L/kg) [136]. In another study, critically ill infants had large 
initial VD from aggressive fluid resuscitation resulting in high variability in maximum 
concentrations and elimination half-lives [137].
Vancomycin PK was also reported to be altered in infants receiving ECMO: mean (± SD) 
steady state VD of 1.1 (± 0.5) L/kg, CL of 0.78 (± 0.19) mL/min/kg, and half-life of 16.9 
(± 9.5) h [84]. Infants undergoing ECMO had a VD that was increased by 50%, a lower CL, 
and a prolonged half-life up to 100% compared to published reports in non-ECMO treated 
infants [84,140,141]. In addition, the hemofiltration CL in a 4-month infant on continuous 
veno-venous hemofiltration (CVVH) receiving vancomycin and tobramycin was increased 
(CL 0.27 to 0.80 mL/min for vancomycin and CL 0.32 to 0.91 mL/min for tobramycin), 
which required dosage modification for both vancomycin and tobramycin [138]. Thus, the 
PK values for vancomycin, especially the VD, are highly variable in critically ill children 
and more vigilant vancomycin drug monitoring might be necessary in this population.
Teicoplanin—Teicoplanin is a glycopeptide antibiotic with a similar antibacterial spectrum 
to vancomycin, but with a more favorable side effect profile and it is available as an 
intramuscular and intravenous formulation [142]. Although teicoplanin might be preferable 
in children due to its longer half-life and ease of administration, only one study has studied 
the PK in critically ill children. In this study of 21 children ranging in ages from 7 days to 12 
years, the mean central volume was 0.38 L/kg, the terminal half-life was 17.4 hours, and 
total CL was 45 mL/h/kg [143] These PK parameters were comparable to non-critically ill 
(ages 2–11 years) children: VD of 0.31–0.68 L/kg, half-life of 6.5–18.1 hours, and CL of 
29–51 mL/h/kg [144]. However, only 11% of trough levels were greater than 10 mg/L, 
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which is considered a desirable trough level in children. The authors concluded that some 
critically ill children might have lower levels of teicoplanin because of an increased VD, 
possibly due to altered plasma protein concentrations and volume expansion treatment, 
diuretics, or from the excess volume administered from multiple drug infusion [143].
Antifungals (Azole Antifungals)
Triazoles are commonly prescribed antifungals with activity against many Candida species. 
The triazole antifungals that are FDA approved and commonly used in children include 
fluconazole, voriconazole, and posaconazole. The triazole antifungals undergo hepatic 
metabolism and have the potential to inhibit CYP450 enzymes. One exception is that 
fluconazole exhibits minimal metabolism and is primarily eliminated in the urine. 
Posaconazole has not been used as frequently in children because the oral formulation 
requires a high-fat meal for optimal absorption and the safety and efficacy of the intravenous 
formulation has not been established in children [145,146].
Fluconazole—Fluconazole is used in children to treat oropharyngeal, systemic, and 
invasive candidiasis, cryptococcal meningitis, and other fungal infections. Fluconazole PK 
parameters were highly variable in 8 critically ill infants (median gestation age at birth of 37 
weeks and postnatal age of 17 days) with median (interquartile range) CL values of 16 (13–
21) mL/h/kg, VD of 1051 (858–1461) mL/kg, and a half-life of 56 (26–80) h [147]. These 
PK parameters were comparable to non-critically infants (median gestation age at birth of 26 
weeks and postnatal age of 16 days) with a CL and VD of about 22 mL/h/kg and 1004 
mL/kg for a 32 week gestation infant, respectively [148]. Another study in 40 critically ill 
children with median (range) age of 22 days (1 day to 17 years) reported that the median 
(range) population VD was 45% higher in children receiving ECMO compared to critically 
ill children not on ECMO [1.35 L/kg (0.81–1.81) versus 0.93 L/kg (0.55, 1.37)] while CL 
estimates were similar [0.018 L/kg/h (0.011–0.043) versus 0.018 L/kg/h (0.008–0.042)] 
[149]. The higher VD in children receiving ECMO is likely due to the large volume of 
exogenous blood required to prime the circuit [149]. Additionally, one study reported that 
fluconazole trough levels were significantly lower in children with cancer [150].
Voriconazole—Voriconazole has extended coverage compared to fluconazole and has 
activity against yeasts and molds including Candida krusei, Candida glabrata, and 
Aspergillus. Voriconazole is used to treat invasive and pulmonary aspergillosis [146]. A 
single case report studied the PK parameters of voriconazole in a 17 year old adolescent 
male before and during ECMO. Before ECMO, the half-life was 24.7 hours, VD was 1.58 
L/kg, and CL was 47.91 mL/min [151]. During ECMO, the half-life decreased to 21 hours, 
the VD decreased slightly to 1.38 L/kg, and the CL increased slightly to 49.33 mL/min 
[151]. Peak and trough levels were similar on the first day of ECMO compared to levels 
prior to ECMO, despite the fact that the dose increased from 280 to 400 mg twice daily to 
account for the loss due to binding [151]. However, two days after starting ECMO, the peak 
and trough levels increased and the patient experienced liver toxicity. The authors speculate 
that voriconazole initially was sequestered in the circuit but that plasma concentrations 
began to increase after binding sites in the circuit were saturated [151].
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Antivirals
Acyclovir—Acyclovir is an antiviral drug commonly used to treat neonatal herpes simplex 
infections. Only one study has investigated the PK of acyclovir in critically ill neonates with 
varying degrees of renal and hepatic dysfunction [152]. In this study, neonates with a median 
(range) gestational age of 38 weeks (27–40) had wide variability in PK parameters with CL 
ranging from 0.03–0.27 L/hr/kg, half-life ranging from 3.8 to 44.5 hours, and mean steady 
state VD ranging from 0.42 to 6.51 L/kg [152]. These PK parameters were similar to 
children up to 3 months of age with normal renal function: mean CL (0.268 L/kg/h), mean 
steady state VD (1.08 L/kg), and mean half-life (3.80 hours) and to adults with varying 
degrees of renal function [152,153]. As expected based on acyclovir’s renal elimination, 
half-life was correlated with serum creatinine concentration: 5.0 hours for serum creatinine 
< 1 mg/dL and 15.6 hours for serum creatinine > 1 mg/dL [152]. The authors concluded that 
neonates with hepatic or renal dysfunction accumulate acyclovir when dosed without 
adjustment for organ dysfunction [152].
Oseltamivir—Although influenza is usually self-limiting in healthy adults, it can result in 
hospitalizations and mortality in infants and young children. Oseltamivir is an influenza 
virus neuraminidase inhibitor used for the treatment and prophylaxis of influenza infection 
[154]. Oseltamivir is given as the pro-drug, oseltamivir phosphate, which is then converted 
to the active form, oseltamivir carboxylate by hepatic esterases. In critically ill infants and 
children (ages 0–12 years) receiving intravenous oseltamivir, oseltamivir carboxylate AUC 
from 0 to the last sample time point (3.67 to 12 hr) ranged from 1,700 to 11,500 ng*hr/mL 
compared to an AUC from 0 to 24 hr of 2410 and 1850 ng*hr/mL in non-critically ill 
children with ages 3–5 and 1–2 years, respectively [155,156]. In addition, the oseltamivir 
carboxylate AUC from 0 to 12 hours ranged from 987.1 to 10,642 ng*hr/mL in three 
children receiving the oseltamivir suspension through the nasogastric or duodenal tube 
during ECMO administration [157]. Two of these children had higher oseltamivir 
carboxylate plasma concentrations compared to children and adults not on ECMO, while the 
third child had suboptimal plasma concentrations due to gastric bleeding and decreased 
gastric motility [157]. The authors concluded that ECMO support does not appear to 
significantly alter oseltamivir PK although further studies are needed [157]. Although 
oseltamivir had elevated exposure in some critically ill children, it was well-tolerated in this 
study.
Analgesics
Fentanyl—Fentanyl is an analgesic drug administered to critically ill children experiencing 
severe pain or agitation. Fentanyl PK data in critically ill children is limited. One study 
reported an increased VD and prolonged elimination half-life after continuous administration 
in 7 critically ill children (mean gestational age 32 ±4 weeks compared to that reported in 
adults and older children [158]. The authors concluded that this was likely due to the age-
related developmental changes in younger children (e.g., changing fat and muscle masses, 
total body water and extent of protein binding) [158]. It was suggested that fentanyl dosage 
must be individually titrated to achieve optimal PD effect in critically ill children [158].
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Anticonvulsants
Levetiracetam—Levetiracetam is used for the management of status epilepticus in 
critically ill children. It is <10% protein bound, is not extensively metabolized via the 
cytochrome P450 pathway, and is largely eliminated unchanged by the kidneys [159]. 
Because of these characteristics, levetiracetam has a lower susceptibility to drug interactions 
compared to other antiepileptic drugs [160]. Prior studies have evaluated the PK of 
levetiracetam in critically ill children with epilepsy [160–164]. Levetiracetam PK in adults 
and children has been reported to be different [161,165]. In children with epilepsy (2–46 
months of age), a shorter mean half-life (5.3±1.3 hours) and a more rapid oral levetiracetam 
CL (1.46±0.42 mL/min/kg) relative to healthy adults (6–8 hours and 0.96 mL/min/kg, 
respectively) were reported [161,165]. The authors suggest that these PK changes may be 
due to the age-related physiological differences in children with epilepsy versus adults 
[2,166].
Lorazepam—Lorazepam is an anticonvulsant used for the treatment of epileptic seizures. 
Two studies have evaluated the PK of lorazepam in critically ill pediatric patients [167,168]. 
Both of these studies have reported that the PK of lorazepam is different in critically ill 
children as compared to adult patients. A PK study in 10 critically ill neonates (median 
[range] gestational age of 40 weeks [37–41]) with seizures had a mean (± SD) decreased VD 
(0.76 L/kg [± 0.37]) and CL (0.23 mL/min/kg [± 0.11]) compared to healthy adults (1.3 L/kg 
and 1.21 mL/min/kg, respectively) [168,169]. Consequently, the elimination half-life in 
critically ill neonates was much higher (40.2 hours) relative to adults (12.9 hours) [168,169]. 
The authors suggest that these differences in VD may be due to a lower percentage of 
adipose tissue (as a fraction of total body weight) in neonates or secondary to differences in 
protein binding compared to the adult population [168]. Similarly, the reduced CL in the 
critically ill neonatal population may be due to reduced glucuronidation of lorazepam 
compared to adults [168].
Gastric acid suppressants
Ranitidine—Ranitidine is commonly administered to critically ill children with upper 
gastrointestinal bleeding and stress-related mucosal damage. One study reported mean 
values for CL of 836 mL/hr/kg, VD of 1.61 L/kg, and half-life of 2.1 hours in 9 critically ill 
children [170]. Another study in 13 term neonates undergoing ECMO reported a reduced 
mean (±SD) CL (252 mL/hr/kg [±154]), comparable VD (1.8 L/kg [± 0.55]) and increased 
half-life (6.6 hours [± 2.75]) compared to infants not being on ECMO [171]. The authors 
suggested that these changes may be due to a reduced glomerular filtration rate in some of 
the neonates undergoing ECMO [171]. Another study reported that ranitidine CL in 
critically ill children increased during the study period possibly due to concomitant 
administration of CYP inducers resulting in a reduced efficacy when recommended doses 
were administered [172]. All studies report that the ranitidine PK is highly variable in both 
critically ill adults and children and thus it is not possible to reliably compare the alterations 
[170–174].
Omeprazole—Omeprazole is a proton pump inhibitor commonly used for different 
gastrointestinal conditions in critically ill children. Although widely used, limited studies 
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have reported the PK of omeprazole in critically ill children [175–177]. Most studies 
reported that omeprazole PK was variable in critically ill children and the overall PK 
parameters were similar to those reported in adults [175–177]. Further studies are required 
to study omeprazole PK in critically ill children with different age groups and disease 
conditions.
Sedatives
Midazolam—Midazolam is commonly used in critically ill pediatric patients because it has 
a rapid elimination compared to other benzodiazepines [178]. Previous studies have shown 
that midazolam CL increases with age and weight in pediatric patients [179,180]. One study 
investigated the PK of midazolam in critically ill children divided in different age groups: 
group 1, infants < 12 months (n = 16); group 2, children 1–2 years (n = 12); and group 3, 
children age 3 years and older (n = 10). Midazolam CL in children 1–2 years of age was 
lower compared to children 3 years of age and older (CL 2.3 mL/min/kg versus 13 
mL/min/kg) [179,181]. However, a recent study in children 1 month to 17 years of age 
showed that while age and weight did not have an influence on CYP3A mediated clearance, 
critical illness was an important determinant of reduced midazolam CL in children [182]. 
The authors concluded that this may be due to reduced CYP3A4/5 activity secondary to 
inflammation that occurs with critical illness [182]. Another study performed in 83 critically 
ill children demonstrated that inflammation and organ failure can significantly reduce 
midazolam CL likely due to an alteration of cytochrome P450 3A-mediated metabolism. In 
this study, C-reactive protein levels and the number of failing organs (cardiovascular, renal, 
respiratory, hematologic, or hepatic), in addition to body weight, were used as continuous 
covariates on midazolam CL. Based on modeling and simulation results, the authors 
concluded that critically ill patients receiving CYP3A substrates may be at a higher risk of 
toxicity due to increased drug levels [183].
Propofol—Propofol is a frequently used sedative in children and adults, and several 
pediatric studies have investigated the effect of critical illness on its disposition [184–188]. 
In a PK study of propofol administered to 28 critically ill, mechanically ventilated children 
(age 0.1–182 months), the disposition was reported to be comparable to previous studies in 
adults [184]. However, another study reported that propofol CL was reduced and steady-
state VD was increased in children that had undergone cardiac surgery [188]. The authors 
concluded that the increased VD was likely due to reduced plasma protein binding associated 
with critical illness [188].
Vasopressors and inotropes
Dobutamine—Dobutamine is used off-label for the treatment of hemodynamic 
insufficiencies and cardiac failure in critically ill children [189,190]. Dobutamine PK in 
critically ill children has been studied in several clinical trials [191–195]. Wide variability in 
dobutamine PK has been observed in pediatric patients as in the adult population [191–196]. 
Across four studies in critically ill children, the mean (range) CL was 94.2 mL/min/kg (40–
178) [191–193,197,198]; with wide ranges of dobutamine CL observed in all studies and 
one study reported a CL range of 12.5–1319 mL/min/kg [195]. The mean (range) VD in 27 
PICU patients (aged 1 month to 16 years) was 1.13 L/kg (0.07–5.64), which is slightly 
Thakkar et al. Page 14
Pharm Res. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
higher than that reported in adults with severe heart failure (0.202 L/kg) [195,198,199]. 
Given that dobutamine is a hydrophilic drug, this difference may be due to the fluid shifts 
resulting from critical illness. Despite the variability in PK across various studies, the 
observed PD of dobutamine in critically ill children has been less variable and increases in 
heart rate and blood pressure have been reported. Thus, additional studies are needed to 
better understand the sources of variability in dobutamine PK in critically ill children.
Dopamine—Dopamine is administered to critically ill children for the treatment of cardiac 
failure and shock. Dopamine PK in critically ill children has been studied previously in 
children with a gestational age (range) of 27–42 weeks [200,201]. The mean (range) CL and 
VD of dopamine were reported as 115 mL/min/kg (62–168) and 1.8 L/kg (0.6–4) [200]. 
Limited information is available on dopamine disposition in critically ill adults and one 
study reported a lower dopamine CL with a mean (± SD) of 70 mL/min/kg (±36) [202].
Epinephrine and norepinephrine—Epinephrine and norepinephrine are catecholamines 
that are exogenously administered to critically ill children during cardiopulmonary 
resuscitation, anaphylaxis, or to prevent low cardiac output following cardiopulmonary 
bypass surgery. There is a significant variability in the PK and PD of exogenously 
administered epinephrine and norepinephrine. Several studies have investigated the PK/PD 
of epinephrine [203,204] and norepinephrine [205] in critically ill children. In critically ill 
children ranging from 0.5 to 16 years of age, epinephrine was reported to have a CL ranging 
between 15.6–79.2 mL/min/kg and the PK was characterized by a one-compartment model 
with linear elimination. Epinephrine CL in critically ill children was lower than reported in 
one adult study (mean [± SD] CL 144.8 mL/min/kg) [203,204,206]. The authors suggested 
that this may be due to changes in combination of different factors (e.g., plasma 
concentrations of platelets, electrolytes, calcium, caffeine) that alter the PK of 
catecholamines in critically ill children [204]. Similarly the CL of norepinephrine was 6.6 
L/h/kg and the PK was well-characterized by a one-compartment model with linear 
elimination [205]. However, there was no difference in the PK of norepinephrine in critically 
ill children relative to adults [205].
CONCLUSIONS AND FUTURE DIRECTIONS
In summary, drug disposition in critically ill children in some cases is unaltered, whereas for 
other widely used drugs the PK is altered and highly variable in this patient population. 
These PK alterations may be due, at least in part, to physiological and developmental factors 
that can dictate differences between children and adults. Additionally, critical illness and 
disease state changes can significantly affect the PK of drugs. Collectively these PK changes 
can lead to altered PD outcomes in critically ill children. For example, the PK of ranitidine 
was variable in critically ill children leading to reduced target attainment of gastric pH 
control despite treatment with the recommended doses [172]. Similarly, the altered PK of 
vancomycin in critically ill children may have resulted in reduced antimicrobial efficacy as 
evidenced by only half of critically ill children reaching target vancomycin AUC24/MIC 
ratio of >400 in a single center study of 22 children [136]. Thus, in both cases, the authors 
highlight the requirement for appropriate dose adjustments to attain optimal efficacy in 
critically ill children [136,172].
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PK/PD changes in children may vary during a treatment period and dose adjustments 
(upward or downward titration) may be needed over time. Although efforts have been made 
to study PK alterations in critically ill children, the small sample sizes and extreme 
variability observed affected the overall conclusions that could be drawn from some studies. 
Additional clinical studies are needed to better understand the impact of PK/PD changes for 
drugs with a narrow therapeutic index, large molecule drugs, and for those that are 
predominantly eliminated through the hepatic and renal pathways. Disease mediated 
changes during critical illness highlight the need for developing robust disease progression 
models in this population. Future clinical trials should study the role of biomarkers when 
evaluating the influence of critical illness over time. In some cases, treatment of critically ill 
patients can be adjusted based on corresponding levels of biomarkers. For example, 
ventilator settings can be adjusted based on oxygen saturation or partial oxygen pressure 
(pO2) measurements over time [207,208]. Also, a high C-reactive protein (≥ 75 mg/L) 
measured within 24 hours before ICU discharge was found to be associated with an 
increased risk of adverse outcome after ICU discharge [209]. Cardiac biomarkers such as 
lactate, troponin, or B-type natriuretic peptide have all shown some utility in the assessment 
of children with critical cardiac disease, mostly when their overall temporal trend, rather 
than a single measurement, are analyzed [210]. In a retrospective review of infants and 
children after heart surgery, persistent elevation of plasma lactate levels >2 mmol/L for 24–
48 hours was a superior predictor of mortality compared to initial or peak plasma lactate 
levels [211]. In the pediatric septic shock population, cardiac troponin elevation at the time 
of admission has been associated with myocardial depression and disease severity [212]. 
The use of biomarkers to guide pharmacotherapy in critically ill children holds great 
promise, but population specific validation and PK/PD studies are needed to identify 
clinically relevant biomarkers that can help guide appropriate treatment adjustments over 
time [213].
Further efforts should be made to elucidate the effect of therapeutic interventions such as 
ECMO and CRRT on PK alterations. Additionally, critically ill children with impaired organ 
function may be at a higher risk of DDI when concomitant medications are administered. 
Last, critical illness may alter drug efficacy and safety and future studies should be designed 
to better understand the effect of critical illness on clinical and PD outcomes. Because 
changes in PK/PD can lead to potentially sub-therapeutic or toxic levels of drugs in critically 
ill children, clinical studies in this vulnerable population are important for rational dose 
selection.
ABBREVIATIONS
AAG α-1 acid glycoprotein
AKI Acute Kidney Injury
ARC Augmented Renal Clearance
AUC Area under the concentration versus time curve
CHF Congestive Heart Failure
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CKD Chronic Kidney Disease
CL Clearance
CRRT Continuous Renal Replacement Therapy
CVVH Continuous Veno-Venous Hemofiltration
CYP Cytochrome P450 enzymes
ECMO Extracorporeal Membrane Oxygenation
ESRD End Stage Renal Disease
PD Pharmacodynamics
PICU Pediatric Intensive Care Unit
PK Pharmacokinetics
VD Volume of Distribution
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Figure 1. 
Factors that may cause pharmacokinetic/pharmacodynamic changes in critically ill children.
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Figure 2. 
Challenges associated with performing studies in critically ill children.
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